Major US Expert Group to Vote on Altering Infant Hepatitis B Vaccine Recommendation

Following a postponement and a remarkably divisive gathering, a federal vaccine advisory panel was set to cast ballots on Friday concerning altering the enduring advisory that each baby be inoculated against hepatitis B.

Intense Discussion and a Deferred Vote

The opening session of the conference on Thursday was marked by intense argument over limiting availability to the hepatitis B vaccine for infants and a choice to postpone the decision by a day to provide committee members extra time to examine the language. The committee, which guides the CDC on vaccination protocols, had twice before postponed.

“Is there any definitive data of damage of giving this vaccination before 30 days? Or is this speculation?” questioned one adviser.

In reply, another attendee stated, “There is scant proof about the enduring danger.”

Present Protocol and Possible Consequences

The shot is currently recommended for each baby within 24 hours of being born to halt contraction of hepatitis B, which can cause major damage to the liver. It has been provided to 1.4 billion people for more than three decades.

The Atlanta conference offered no recent proof of injuries resulting from the vaccine. Authorities state any modification to the current hepatitis B vaccination schedule could have major and extensive implications for pediatric well-being in the United States.

Panel Composition and New Appointments

The consultative group can only make recommendations to the director of the CDC. The committee's composition has experienced alterations in recent days, with the statement that the panel's latest chairman would leave for an agency job and be substituted with a cardiac doctor who has been questioning of other immunizations.

The committee includes a number of vaccine skeptics who support a aim to revamp – and perhaps, in some cases, scrap – long-established immunization guidelines.